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Brief Clinical Reports
Diagnosis in the Neuroleptic
Malignant Syndrome
James H. Dallman, M.D. , C.P.T., M.C.

INTRODUCTION

Neuroleptic ma lignant syndrome (NMS) is an uncommon, potentiall y le thal
complication of treatment with antipsychotic medication. First described in
America n journals by De lay and Deniker in 1968 (1), this syndrome has been
reported for many years in th e European and Japanese literature.
Neuro leptic malignant syndrome is characterized by fever, altered men tal
status, autonomic dysfunction, and generalized skeletal muscle ri gidity. Its
appearance usually fo llows use of high potency neuroleptics in th erapeu tic
doses . In the American literature, most reported cases have re sulted fr om use of
haloperidol, fluphenazine, thiothixene or piperazine d eri vatives (2,3). Longacting depot fluphenazine has been particularly implicated (4,5). One reported
case has been attributed to thioridazine therapy (6), and a n ot her to tetrab e nazine and alphamethyltyrosine therapy (3).
Features of NMS are also described following use o f neuroleptics in
co nj u nct io n with lithium salts and tricyclic antidepressants, a nd in sed at ive
withdrawal syndromes (7,8). While persons of all ages ma y be affect ed , nearl y
75 % are under age 40 , male-to-female ratio being 2: 1 (5).
CASE REPORT

A 22-year-old housewife in her eighth month of pregnancy d e vel oped
emotional labi lity which continued until the uneventful delivery of a health y
baby boy at te rm . Following discharge from the hospital , th e patient did well
unti l t hree wee ks post-partum, when her husband noted that she was exhibiti ng
strange behavior. She wo u ld cry unexplainably and 'speak repeatedl y o n
religious themes. O n several occasions, she made telephone calls to her friends
stating that their parents had died. Her speech became increasingly incoherent
and fragmented, with perseveration of ideas. She began to neglect he r housework and personal hygiene, appearing self-absorbed. The patient was referred
for psychiatric evaluation and admitted to a local hospital.
Dr. Dallman wrote this paper while a fourth-year resident at Letterman Army Medical Center,
San Francisco, California.
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Shortly after ad miss io n, th e pati ent d em o nst rated restlessness and psych omotor agitation warran t in g an intramuscul a r injectio n of ha loperidol, 2. 5 mg.
Foll o wing ad m in istr atio n of t he medication , she exh ib ited robot-like movements , muscular rigidity, and oculogyri c cr isis. Also noted we re h ypo kinesia ,
psychomotor retardati on , drowsin ess, a n d tongue protrusion . T r eatment wit h
haloperidol, 2 mg dail y, was conti nued. On th e eig h th h o sp ita l day, th e patient
became unresp onsive and incon t inen t o f urine and feces. By ho sp ital da y ten , she
required co ntin uous nursing ca re . Intravenous fluid s were adm inistered a nd
haloperidol was di scontinued. Within two d ays, the pat ie n t became more
responsi ve and was able to reco gnize her sp ouse .
Twel ve days afte r ad m issio n to her loca l ho sp ital , the patient was transfe rred to o u r faci lity. Ph ysical exami na tion noted a n indwelling urinary cat heter, large bli sters o n both heel s, a protruding tongue with hyp e r sali vat io n , a nd
ath etoid mo vements o f t he upper ex trem it ies . T he fo llowi ng d ay, the patie nt
showed in creasing agitation, and thiothixen e , 4 0 m g o ra lly, was given . Within
24 hours, she was noted to be di aphoreti c a nd tach ycard ic. A ll neuroleptic
medications were di scon tinu ed , and in th e ensu ing fo ur da ys she improved . O n
th e n inth hospital day, because of her inc reasing para noia and accompan ying
ag ita tio n, the pati ent was g ive n a dose of hal operidol , 10 mg in tramuscularl y.
Within 24 hour s, she d ev eloped extreme muscular rigidi ty, di apho resis, ta ch ycar d ia, and h yp e rsali vation. H er mental sta tus became increasingly st upo rous
and t he foll owin g d ay she d e vel oped h ype rthe rmia (38 .6°C, 10 1.5°F), wh ich
last ed for ap p rox ima tely two d a ys. A slo w reco ve r y fo llowed with the di scon t inuation o f a ll neuroleptic medication . She was di sch arged after 16 days in the
hospital with no persist ent sid e-effects.
C LIN IC A L C HA RACTER IST ICS

C lassica lly, N MS is ch aract eri zed b y th e tr iad of mu scul a r r igidity, h ype rth ermia , a nd altered co nscio usness (9). Recent d escriptions a lso includ e autonomic d ysfun cti on (2 , 10) . Symptoms usu all y begin soon afte r starting or increasing t he dosage of ne urolep tics . O nset of the syndrome ma y occur within ho urs,
or ma y be d e layed fo r severa l months fo llowi ng in itial drug expo su re. So me
N MS patien ts have reported p re vious as ym ptomatic ex posure to neuroleptics: in
other cases neuroleptics ha ve been resta rted wit hou t recu rren ce of NMS after
th e ac u te syndrome is resol ved (2).
It is not clea r why suc h va r iations ex ist. Perhaps neuroleptics may be
necessary but are no t in th e m sel ves suffic ient to induce the syndrome. Itoh (10)
noted th at ph ysical ex ha us t io n associate d wit h d eh ydration was a n underlyin g
co nd it io n of NMS in all 14 pati en ts studied, suggesting th at d eh yd rat ed and
d ebilitated sta tes ma y at least predispos e or con tr ib u te to o nset of NMS. In o u r
patient , th e post-partum sta te was present.
A mong th e earliest sig ns of MS are extrapyra mi dal rigidity and in voluntary mo veme nts, so me ti mes accom pan ied b y dysa r th r ia and d ysphagia . H ype r-
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thermia, appearing after the extrapyramidal signs, may reach 41 0 C (10 5 0 F), or
may be only moderately elevated (2). Consciousness is altered and can ap pear as
a dazed mutism (similar to catatonia) with subsequent progression to st upor,
coma, and death (2).
Autonomic dysfunction includes pallor, diaphoresis, sialorrhea , blood p ressure instability, tachycardia, pulmonary congestion, and tach ypnea . In some
cases, tachypneic hypoventilation from decreased chest wall compliance necessitates respiratory support. Dehydration is common and ma y progress to ac u te
renal failure in the absence of myoglobinuria. Less frequent signs are ocul o gyri c
crisis, opisthotonus, seizures, chorea, Babinski signs, and trismus.
Symptoms usually resolve within five to ten days after stoppi ng ora l
neuroleptics but last for several weeks after long-acting depot inj ection s. In 16%
to 30 % of cases fatalities have occurred from acute renal failure , respi rat o r y
failure, or cardiovascular collapse (2). Death has been more common among
those who receive depot fluphenazine, probably because of its p rolonged
half-life. Postmortem examinations of the central nervous system have revea led
no consistent abnormalities.
Laboratory findings frequentl y are normal. Transient elevati on of serum
aldolase or creatinine phosphokinase (CPK) has been repeatedl y observed .
Laboratory concomitants of dehydration can be see n , a nd liver paren ch ymal
enzyme elevations have been noted. Leukocytosis with a pol ym orphonuclea r cell
predominance is co m mo n without other evidence o f infecti on . T he sed imentation rate ma y be e le vated . Cerebrospinal fluid is normal , as is th e co mpu terized
tomography scan . The electroencephalogram ma y be normal or nonspecifica lly
slow, suggesting diffuse metabolic encephalopathy .
DIFFERENTIAL DIAGNOSIS

Hyperthermia and altered mental status are ca rd ina l signs of C NS infections, therefore, NMS is most often mistaken for an infection. Bact erial, fu nga l
and parasitic infections, viral or syphilitic encephalitis, and e ven tetanu s m ust be
ruled out in the differential diagnosis. Occasionally, trauma o r neoplasms can
produce akinetic mutism and h yperthermia of a central o r igin which a lso
resembles NMS.
Drug allergy should be considered. One must look for eos inop h ilia and
cutaneous abnormalities suc h as erythema or rash. H ypertonicity in N MS is
similar to extrapyramidal rigidity and must be differentiated fro m basal ganglia
dis eases such as severe Parkinson 's di sease. Other disorde rs of muscle hypertonicity such as decerebrate and decorticate rigidity, tetany, and spasti cit y m ust be
ruled out.
Catatonia ma y resemble NMS. The classic signs of ca ta to n ia, inclu d in g
ca ta lepsy and wax y flexibility, negativism , mutism , muscula r r igid ity, and
bizarre mannerisms can be present in
MS ( 1 1). Catatonia is a no nspecific
descriptive syndrome which can result from metabolic, infectious, psychi at r ic,
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or structural brain disorders. In " le tha l catatonia," sus ta ined agi tation progresses to withdrawal, stupor (12,13 ), h ypotension , hyperth erm ia , a nd death in
days to weeks.
If the patient has been exposed to a hot environment, heat st ro ke should be
considered, especially if anticholinergic drugs have been give n as they can
inhibit sweat ing . In heat stroke, as in NMS, h yp e rpyr exia and a d epressed level
of consciousness occur, but extrapyramidal signs p ri or to tempe rature e levation
are lacking.
Finally, malignant h yperthermia (MH) must be co ns idered in that hyperthermia , rigidity, a nd CPK elevation occur in both syn d romes, and they may
have a co m mo n pathoph ysiology (2 , 12, 14) . In a bout o ne-t hird of the cases of
MH, predisposition is transmitted as an autosomal dominant trait; fa m ilial MS
has not been reported. Serum CPK, which is markedly el ev at ed du ri n g MH, may
also be increased in patients between attacks or among asy m ptomatic family
members. Most patients with NMS have normal seru m CPK befo re and after
each episode. Mortality from MH approach es 70 %, wh ereas among cases of
NMS it is less than 30 %.
PATHOGENESIS

T he exact pathogenesis o f N MS remains unclear. A popu la r hypothesis
suggests a peripheral mechanism , mainly because of th e clinical similarities
between NMS and anesthetic-induced malignant hyp ertherm ia ( 15). Studies
have indicated that MH may result from excessive release of ca lcium into
ske le tal muscle cytoplasm due to altered membrane transport of ca lciu m in the
presence of cer ta in drugs (15) . Exc ess intrac ellular ca lciu m co uld cause the
rigidity and the subsequent hyperpyr exia seen in both MH a n d N MS.
Some a u t ho rs (2, 12 , 16) ha ve po stulated th at th e di sturba nce of N MS is primaril y ce n tra l, su ggesting that d opamine receptor block ade o r dopamine depletion in th e ba sal ganglia , hypothalamus , o r brain stem is th e mai n pathophysiologi c mechanism . Impaired th ermoregulation b y neuroleptic d r ugs which block
dopamine receptors, is seen both clinicall y a nd ex per imen ta lly. Dopa m ine and
related neurotransmitters are fo u nd in th e h ypothal amus, a n d do pam ine receptors of th e 0-1 class, whi ch mediate th ermoregulation , a re locat ed in the
preoptic anterior h yp othalamus. Th e mesolimbic dopaminergic path ways may
also playa rol e in th ermoregulation .
H yperpyrexia ca n result from e levat io n of the h ypothalamic "set-point,"
impaired heat di ssipation mechanisms, or excess heat p roduct io n . Beca use
patients with NMS swea t profusel y, so m e peripheral routes of heat dissipation
are intact. Howe ver, vasoco ns tr ictio n is seen in neuroleptic-treated animals
made h yp erthermic, a nd pallor in N MS patients sug ges ts that th e re is peripheral
vasocons tr ictio n which prevents heat transfer fr om th e body core to the
environment. A consid erable amount o f heat is generated by th e profound
rigidity and tremors seen in NMS. Th ese extrapyramidal sig ns p recede , and
probabl y co n tr ib ute to, the hyperpyrexia.
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TREATMENT
To achieve results in treating NMS, symptoms must be recognized early and
all psychotropic medications must be promptl y withdrawn . Until recently,
medical treatment of NMS was limited to sym p to ma tic th erapy with intensi ve
supportive medica l care, with particular attention to maintenance of res p iratory, re nal , and cardiovascular systems. Vigorous treatment of h ype rthe r m ia as
we ll as maintaining fluid and electrol yte balance has al so bee n impo rta n t.
Rece nt reports describe successful pharmacologic treatmen t of NMS usin g
dantrolene sodium (17,18,19) . Dantrolene, a direct- acting skeleta l m uscl e relaxant with unclear central effects, has been shown to be e fficac io us in trea tin g
ma lignant hyperth ermia in animals and humans. In muscles, it di ssociates
excitation-contraction coupling b y inhibiting the rel ease of ca lcium ions fr om
the sarcoplasmic reticulum (SR) through action s on th e tran sverse tubula r
membrane-S R coupling, on SR directly, or both (20). Do sages of 50 mg orally
taken two to four times daily have r esulted in rapid clinical impro veme nt a nd
sh o rte ned the duration of NMS from the usual five to ten days to less th a n th ree
days. Further use of this agent in NMS patients is warranted to d ete rm ine its
efficacy, optimal dosage, and route of administration. Other pharmacologic
therapies have been aimed at directl y altering the CNS dopaminergic/ ch o line rgic ratio through adm inistration o f anti-Parkinsonian age nts. McCarro n et a l.
(21) and Amdurski et al. (22) recentl y reported success fu lly treatin g NMS with
amantadine. Br o mocrip tine has also been tried (23).
SUMMARY
Neuroleptic ma lignant syndrome is a rare but underreco gn ized co m plicat ion of neuroleptic therapy characterized b y generalized ske leta l muscle r igidi ty,
h yperthermia , autonomic d ysfunction , and a ltered consciousness. Recogn itio n
of NMS and immediate withdrawal of neuroleptics usually leads to co m plete
recovery. Fail ure to recognize this synd ro me can increase th e ri sk o f morbidity
and ma y lead to d eath in a significant percentage of patients. T he patho ge n esis
of NMS remains unknown, but both peripheral and central mech ani sms ha ve
been proposed. Based on these h ypotheses, there have been reports of su ccessful
treatment using dantrolene sodium, a peripheral muscle relaxant a nd ce n tra llyact in g age n ts such as ama n tad ine. Further stud ies are needed to elucidate t he
cause and optimal treatment of this syndrom e .
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